Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

RADIENT RESTRUCTURED BY A PLANNED REVERSE MERGER

Checkout my next post on how Provista Diagnostics Inc. will reverse merge with Radient Pharmaceuticals Corp according to the Letter of intent...LOI of 2010..After the merger we will be dropping the Radient name ..It will be replaced with Provista you understand...

Keep on hitting these previous I-Hub Links..There is a surprise at the end you understand..It is the "Wolf Code"..Here is the latest..


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117135107


Y I-stat ..They will set up the CIT kits you understand...ahooooooooooooooooooooooooooo

http://www.geniepi.com/en/products



Check out the recent developments by our partner in India thanks to Uni-Pharma and their licensing of Onko-Sure and Cervi-M you understand..Notice who is promoting the partnership, Cervi-M,and onko-Sure, and CIT... (ingenuity health care)backed by Bhatia's relatives...262 shares on Ingenuity Health Care Face Book and growing...Sly Stone use to call it a "Family Affair" you understand...ahoooooooooooooooooooooooooooooooooooooooooooooo

https://www.facebook.com/OnkoSureIngenuityHealthcareIndia


Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based pharmaceutical company, announced today it has entered into an exclusive 5-year collaboration agreement with Jaiva Technologies. Under the terms of the agreement, Jaiva Technologies will collaborate with clinical laboratories, hospitals and physicians in India to conduct clinical trials for RPC's Combination Immunogene Therapy (CIT) technology. Additionally, Jaiva will support RPC in securing Indian government approval for the use of CIT as a cancer therapy and vaccine throughout the country.

Jaiva Technologies is a US-based multinational biotechnology company focused on the research and development, distribution, marketing and sales of promising third-party healthcare technology products, including RPC's CIT cancer therapy and vaccine.

Today's agreement supports RPC's expansion and commercialization strategy for its cancer products that also include RPC's FDA-approved Onko-Sure™ in vitro diagnostic cancer test. According to Mr. Douglas MacLellan, CEO of Radient Pharmaceuticals, "We are pleased with today's announcement and look forward to working with Jaiva on the commercialization of CIT in India. We remain steadfast in our efforts to accelerate RPC's market growth and value to our customers, patients, and shareholders."

According to Dr. Umesh Bhatia, Jaiva CEO, "We are very excited to collaborate with Radient Pharmaceuticals on the further development and commercialization of CIT in India. This product has tremendous potential benefit in treating cancer patients, and we believe that, through our extensive network in this market, we will complete the necessary clinical trials to gain government approval and initiate and generate solid product sales."
http://www.marketwired.com/press-release/Radient-Pharmaceuticals-Enters-Into-Collaboration-Agreement-With-Jaiva-Technologies-1166831.htm


$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$


Home About iStat iStat Introduction
iStat Introduction



Background

iStat is a biomedical company dedicated to early cancer detection and health related research. Our operating businesses are organised into two divisions: iStatBIO and iStatHEALTH.



In iStatBIO we specializes in developing and manufacturing easy to use cancer detection products. our service in IStatBIO include diagnostic kit development & manufacturing, ISO/GMP quality system setup and methylation assay for cancers. In iStatHEALTH, we focus on clinical study design, data management and clinical statistical analysis. Our service in iStatHealth include clinical study design, data management, statistical analysis and epidemiology study.



We have obtained ISO 13485/9001 on providing medical clinical research service and on design and manufacture of gene detection kits.



Our pipelines of proprietary products enable doctors to diagnose or screen cancer more accurately and earlier. Our lead product, Cervi-M, is a cervical scrapings based test for early detection of cervical cancer. We have validated our tests with clinical studies which involved 11 hospitals and more than 600 patients in Taiwan.


http://www.geniepi.com/en/products